Aurinia Pharmaceuticals (AUPH) vs Schrodinger (SDGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Aurinia Pharmaceuticals (AUPH) has outperformed Schrodinger (SDGR) over the past year, gaining 36.7% versus a gain of 35.4%. Over five years, AUPH leads with a -22.2% price change compared with -50.7% for SDGR. Aurinia Pharmaceuticals is the larger company by market cap ($2.13 billion vs $2.04 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | SDGR |
|---|---|---|
| Share price | $16.01 | $27.29 |
| Market cap | $2.13B | $2.04B |
| 1-day change | +2.04% | -5.57% |
| YTD return | +0.38% | +52.63% |
| 1-year return | +36.72% | +35.37% |
| 5-year return | -22.17% | -50.70% |
| P/E ratio (TTM) | 7.02 | — |
| Forward P/E | 15.01 | — |
| EPS (TTM) | $2.28 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.25 | $33.78 |
| 52-week low | $10.90 | $10.95 |
| Distance from 52-week high | -16.83% | -19.21% |
| Analyst consensus | none | none |
| Avg. price target upside | +11.56% | -21.47% |
| Average volume | 1.01M | 1.69M |
| Shares outstanding | 133.05M | 65.64M |
| Employees | 128 | 850 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
AUPH vs SDGR FAQ
Which is bigger, Aurinia Pharmaceuticals or Schrodinger?
Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $2.13B compared with $2.04B for Schrodinger (SDGR).
Which stock has performed better over the past year, AUPH or SDGR?
AUPH returned +36.72% over the past 12 months, compared with +35.37% for SDGR (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Schrodinger in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.